Luspatercept (mIgG2a)

Synonyms: RAP-536
Luspatercept (mIgG2a) (RAP-536) 是一种由修饰的人类 ActRIIB 胞外结构域与鼠类 IgG2a Fc 结构域连接而成的融合蛋白,可抑制 β-地中海贫血小鼠中的 Smad2/3 信号传导、促进晚期红细胞前体分化并缓解无效红细胞生成 (IE),同时减轻贫血、α-珠蛋白聚集、溶血以及铁超载、脾肿大和骨缺损等 IE 疾病并发症。
产品编号: MS-R15254 纯度: 99.9% CAS No.: 1373715-00-4
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Luspatercept (mIgG2a) (RAP-536) 是一种由修饰的人类 ActRIIB 胞外结构域与鼠类 IgG2a Fc 结构域连接而成的融合蛋白,可抑制 β-地中海贫血小鼠中的 Smad2/3 信号传导、促进晚期红细胞前体分化并缓解无效红细胞生成 (IE),同时减轻贫血、α-珠蛋白聚集、溶血以及铁超载、脾肿大和骨缺损等 IE 疾病并发症。

生物实验数据

生物活性 Luspatercept (mIgG2a) (RAP-536) is a fusion protein composed of a modified human ActRIIB extracellular domain linked to a murine IgG2a Fc domain that inhibits Smad2/3 signaling in β-thalassemia mice, promotes the differentiation of late-stage erythroid precursors, and alleviates ineffective erythropoiesis (IE), while also reducing anemia, α-globin aggregation, hemolysis, and IE disease complications such as iron overload, splenomegaly, and bone defects.
体内研究
(In Vivo)

Luspatercept (mIgG2a) (RAP-536) (1 mg/kg,皮下注射,每周两次,持续 2 个月) 通过促进 β-地中海贫血小鼠模型中晚期红细胞分化来缓解贫血,减少 α-珠蛋白聚集和溶血,并减轻小鼠的 IE 及相关疾病并发症。
Luspatercept (mIgG2a) (30 mg/kg,腹腔注射,一次,持续 12 小时) 可抑制小鼠 β-地中海贫血小鼠模型中脾脏红细胞前体细胞中 Smad2/3 的过度激活。
Luspatercept (mIgG2a) (1-10 mg/kg,皮下注射,每周两次,持续 2 个月或一次,持续 72 小时) 可促进骨髓和脾脏中的终末红细胞分化,并增加外周红细胞在经 EPO 预处理的野生型小鼠中。

Animal Model: Hbbth1/th1 mice of the B6.D2-Hbbd3th/BrkJ strain (3-4 months old) with hydrogen peroxidenot (50 μM) or not.
Dosage: 1 mg/kg
Administration: s.c., twice weekly for 2 months and then collected bone marrow, spleen and liver tissues.
Result: Significantly increased 29% RBC number, 16% hemoglobin concentration, and 19% hematocrit.
Decreased 8% mean cell volume, 10% mean cell hemoglobin, and 2% mean cell hemoglobin concentration.
Reduced 33% reticulocytes and a 19% red cell distribution width area.
Induced an overall increase in the proportion of late-stage erythroid precursors, significantly decreased the cell population of R1 while an increase of R3 in bone marrow, and reduced R1 and R2 with a significant increase in R3 in the spleen.
Reduced ∼60% serum EPO level, 36% splenomegaly, serum concentrations of ferritin (15%) and iron (28%), 29% transferrin saturation.
Reduced iron levels in liver (1464 μg/mg dry weight) and kidney (648 μg/mg dry weight) and altered the iron distribution with restoration of architecture in spleen.
Increased Hamp mRNA levels approximately 2 times without the expression changes of Bmp6 in liver and Gdf15 or Twsg1 in spleen.
Reduced 40% mean concentrations of total bilirubin and occurrence of abnormal erythrocyte morphology and hemolytic debris, but increased mean erythrocyte life span (28 vs 20 days).
Markedly reduced heinz bodies and 38% mean membrane-associated α-globin aggregates in peripheral erythrocytes.
Reduced ROS levels significantly in immature (CD71+Ter119+) and mature (CD71−Ter119+) erythroblasts as well as in peripheral red cells.
Reduced peroxide-stimulated ROS levels and significantly increased 17% bone mineral density, 100% trabecular bone volume (100%), number (14%), and thickness (14%).
Increased cortical thickness with a decrease in marrow space.
Animal Model: Hbbth1/th1 mice of the B6.D2-Hbbd3th/BrkJ strain (3-4 months old).
Dosage: 30 mg/kg
Administration: i.p., once for 12 h, and then collected bone marrow, spleen and liver tissues.
Result: Reduced phosphorylated Smad2/3 level in erythroid precursors of spleens within 12 h.
Inhibited phospho-Smad2 protein expression in erythroid precursors of spleens within 12 h.
Animal Model: C57BL/6 wild-type mice were injected intraperitoneally with EPO (1500 units/kg) or not.
Dosage: 1, 10 mg/kg
Administration: s.c., (1 mg/kg) twice weekly for 2 months, (10 mg/kg) once for 72 h, and then collected bone marrow, spleen and liver tissues.
Result: Promoted terminal erythroid differentiation in the bone marrow and spleen and increased peripheral red cells in EPO-pretreated wild-type mice at 10 mg/kg with EPO stimulation in C57BL/6 wild-type mice.
Did not affect iron parameters and Hamp expression in C57BL/6 wild-type mice.
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 1373715-00-4
别名 RAP-536

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础